| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
The main coagulation and fibrinolytic factor plasmin, which is derived from its proform plasminogen (Plg) and one of its downstream targets, matrixmetalloproteinases (MMP), have been linked to various malignancies. Here, we provide the evidence that blockade of plasmin reduces lymphoma growth by inhibiting MMP-dependent recruitment of bone marrow derived CD11b+ cells locally within the lymphoma tissue. Genetic Plg deficiency and drug-mediated plasmin blockade delayed lymphoma growth and diminished MMP dependent marrow derived CD11b+ cell infiltration into lymphoma tissues and formation of malignant niche. We could show that CD11b+ cells play key a role in the growth of lymphoma and the other malignancies through malignant niche formation. Collectively, our data demonstrate a previously undescribed role of fibrinolytic system in tumor growth and provide strong evidence that specific blockade of plasmin a promising approach for the cancer treatments.
|
